参考文献/References:
[1] KHONGORZUL P,LING C J,KHAN F U,et al.Antibody-drug conjugates:a comprehensive review[J].Mol Cancer Res,2020,18(1):3-19.
[2] 中国抗癌协会肿瘤药物临床研究专业委员会,国家抗肿瘤药物临床应用监测专家委员会,国家肿瘤质控中心乳腺癌专家委员会,等.抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)[J].中华肿瘤杂志,2021,43(1):1.
[3] MAKAWITA S,MERIC-BERNSTAM F.Antibody-drug conjugates:patient and treatment selection[J].Am Soc Clin Oncol Educ Book,2020,40:1-10.
[4] LEUNG D,WURST J M,LIU T,et al.Antibody Conjugates-recent advances and future innovations[J].Antibodies(Basel),2020,9(1):2.
[5] CHAU,CH,STEEG P S,FIGG W D.Antibody-drug conjugates for cancer [J].Lancet,2019,394(10200):793-804.
[6] LIU F,KE J,SONG Y.T-DM1-induced thrombocytopenia in breast cancer patients:new perspectives[J].Biomed Pharmacother,2020(129):110407.
[7] MASTERS J C,NICKENS D J,XUAN D,et al.Clinical toxicity of antibody drug conjugates:a meta-analysis of payloads[J].Invest New Drugs,2018,36(1):121-135.
[8] ROSENBERG J E,O'DONNELL P H,BALAR A V,et al.Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy[J].J Clin Oncol,2019,37(29):2592-2600.
[9] MASTERS J C,NICKENS D J,XUAN D,et al.Clinical toxicity of antibody drug conjugates:a meta-analysis of payloads[J].Invest New Drugs,2018,36(1):121-135.
[10]BA Y,SHI Y,JIANG W,et al.Current management of chemotherapy-induced neutropenia in adults:key points and new challenges:committee of neoplastic supportive-care(CONS),China Anti-cancer association committee of clinical chemotherapy,China anti-cancer association[J].Cancer Biol Med,2020,17(4):896-909.
[11]中国临床肿瘤学会指南工作委员会.肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J].中华肿瘤杂志,2017,39(11):868-878.
[12]MASTERS J C,NICKENS D J,XUAN D,et al.Clinical toxicity of antibody drug conjugates:a meta-analysis of payloads[J].Invest New Drugs,2018,36(1):121-135.
[13]CLIFFORD K,COPELAND A,KNUTZEN G,et al.Brentuximab vedotin:a nursing perspective on best practices and management of associated adverse events[J].Clin J Oncol Nurs,2018,22(4):103-114.
[14]STRAUS D J,DLUGOSZ-DANECKA M,ALEKSEEV S,et al.Brentuximab vedotin with chemotherapy for stage Ⅲ/Ⅳ classical Hodgkin lymphoma:3-year update of the ECHELON-1study[J].Blood,2020,135(10):735-742.
[15]马飞,刘明生,王佳妮,等.紫杉类药物相关周围神经病变规范化管理专家共识[J].中国医学前沿杂志:电子版,2020,12(3):46-56.
[16]BARROSO-SOUSA R,SANTANA I A,TESTA L,et al.Biological therapies in breast cancer:common toxicities and management strategies[J].Breast,2013,22(6):1009-1018.
[17]TSURUTANI J,IWATA H,KROP I,et al.Targeting HER2 with trastuzumab deruxtecan:a dose-expansion,phase Istudy in multiple advanced solid tumors[J].Cancer Discov,2020,10(5):688-701.
[18]董元鸽,汪洋.化疗致恶心呕吐的临床护理实践方案解析[J].解放军护理杂志,2019,36(7):50-53.
[19]AVILA M S,SIQUEIRA S R R,FERREIRA S M A,et al.Prevention and treatment of chemotherapy-induced cardiotoxicity[J].Methodist Debakey Cardiovasc,2019,15(4):267-273.
[20]CADEDDU DESSALVI C,DEIDDA M,MELE D,et al.Chemotherapy-induced cardiotoxicity:new insights into mechanisms,monitoring,and prevention[J].Cardiovasc Med,2018,19(7):315-323.